Success Metrics

Active Trials
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph early_phase_1
1
25%
Ph not_applicable
1
25%
Ph phase_2
1
25%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Other(1)

Detailed Status

Not yet recruiting2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 21 (25.0%)
N/A1 (25.0%)

Trials by Status

not_yet_recruiting250%
recruiting125%
unknown125%

Recent Activity

1 active trials
Showing 4 of 4
not_yet_recruitingearly_phase_1

Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

NCT07458659
not_yet_recruitingphase_1

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

NCT07043218
recruitingphase_2

Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

NCT06996132
unknownnot_applicable

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

NCT04692948

Clinical Trials (4)

Showing 4 of 4 trials
NCT07458659Early Phase 1

Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Not Yet Recruiting
NCT07043218Phase 1

A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Not Yet Recruiting
NCT06996132Phase 2

Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

Recruiting
NCT04692948Not Applicable

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4